Guangyong Chen

ORCID: 0000-0003-1818-6280
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Ischemic Stroke Management
  • Gastric Cancer Management and Outcomes
  • Mesenchymal stem cell research
  • Colorectal Cancer Surgical Treatments
  • Tissue Engineering and Regenerative Medicine
  • Colorectal and Anal Carcinomas
  • Metastasis and carcinoma case studies
  • Electrospun Nanofibers in Biomedical Applications
  • Renal cell carcinoma treatment
  • Lymphoma Diagnosis and Treatment
  • Inflammatory Biomarkers in Disease Prognosis
  • Renal and related cancers
  • Colorectal Cancer Treatments and Studies
  • Parkinson's Disease Mechanisms and Treatments
  • Gastrointestinal Tumor Research and Treatment
  • Venous Thromboembolism Diagnosis and Management
  • Helicobacter pylori-related gastroenterology studies
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Esophageal Cancer Research and Treatment
  • Animal Nutrition and Physiology
  • Cerebrovascular and Carotid Artery Diseases
  • Pancreatic and Hepatic Oncology Research
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Hypoxia, and Metabolism
  • Genetic factors in colorectal cancer

Jilin University
2018-2025

Beijing Friendship Hospital
2016-2025

Capital Medical University
2016-2025

Ruian People's Hospital
2019-2025

Wenzhou Medical University
2019-2025

Union Hospital
2018-2025

Zhejiang Lab
2025

Center for Life Sciences
2025

Union Hospital
2018-2024

Weatherford College
2024

Adding PD-1 blockade in the neoadjuvant regimens for locally advanced rectal cancer (LARC) patients with microsatellite stable (MSS) / mismatch repair-proficient (pMMR) tumors is an attractive, but debatable strategy. This phase 2, multicenter, prospective, single-arm study enrolled from 6 centers June 2021 to November 2022. Locally (LARC, cT

10.1038/s41392-024-01762-y article EN cc-by Signal Transduction and Targeted Therapy 2024-03-11

The prebiotics inulin (INU) and isomalto-oligosaccharide (IMO) influence intestinal health immunity, but their effects on constipation are not clearly established.

10.1039/d0fo00865f article EN Food & Function 2020-01-01

Systemic immune-inflammation index (SII), a novel inflammation derived from counts of circulating platelets, neutrophils and lymphocytes, has been studied in developing incident cancer. However, the clinical value SII acute ischemic stroke (AIS) patients had not further investigated. Therefore, we aimed to explore association between severity as well 3-month outcome AIS patients.A total 216 receiving intravenous thrombolysis (IVT) 875 healthy controls (HCs) were retrospectively recruited....

10.2147/cia.s311047 article EN cc-by-nc Clinical Interventions in Aging 2021-05-01

Stress hyperglycemia ratio (SHR), calculated as glucose/glycated hemoglobin, has recently been developed for assessing stress and could provide prognostic information various diseases. However, calculating SHR using random blood glucose (RBG) drawn on admission or fasting (FBG) lead to different results. This study intends evaluate the association between functional outcomes in patients with acute ischemic stroke (AIS) recombinant tissue plasminogen activator (r-tPA) intravenous...

10.3389/fnagi.2022.782282 article EN cc-by Frontiers in Aging Neuroscience 2022-02-08

We introduce a new molecular dataset, named Alchemy, for developing machine learning models useful in chemistry and material science. As of June 20th 2019, the dataset comprises 12 quantum mechanical properties 119,487 organic molecules with up to 14 heavy atoms, sampled from GDB MedChem database. The Alchemy expands volume diversity existing datasets. Our extensive benchmarks state-of-the-art graph neural network on clearly manifest usefulness data validating further launch contest attract...

10.48550/arxiv.1906.09427 preprint EN other-oa arXiv (Cornell University) 2019-01-01

Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since combined immune checkpoint inhibitors has been reported to have synergic effects. This study aims explore safety efficacy of long-course concurrent tislelizumab as a neoadjuvant regimen patients cancer. manuscript interim result prospective, multicenter, single-arm, phase II trial. Patients mid-to-low cancer clinical stages cT3-4a N0M0 or...

10.3389/fonc.2023.1057947 article EN cc-by Frontiers in Oncology 2023-02-02

Abstract This study was conducted to investigate the effects of Clostridium butyricum and Enterococcus faecalis on growth performance, immune function, inflammation-related pathways, microflora community in weaned piglets challenged with lipopolysaccharide (LPS). One hundred eighty 28-d-old were randomly divided into 3 treatments groups: fed a basal diet (Con), containing 6 × 109 CFU C. butyricum·kg−1 (CB), 2 1010 E. faecali·kg−1 (EF). At end trial, 1 pig selected from for each pen (6 pigs...

10.1093/jas/skz235 article EN Journal of Animal Science 2019-07-16

High-grade renal cell carcinoma with morphology and immunophenotypic features identical to medullary carcinoma, occurring in a patient without evidence of sickle trait or disease, is proposed be diagnosed as unclassified phenotype (RCCU-MP) classified subtype SMARCB1-deficient the World Health Organization (WHO) 2022 edition. So far, about twelve tumors RCCU-MP have been reported literature. Herein, we extend this observation tumor 39-year-old patient, morphologically similar carcinoma....

10.1177/10668969251316906 article EN International Journal of Surgical Pathology 2025-02-21

Background: Hepatic fibrosis, a chronic pathological condition, is associated with adverse outcomes in stroke patients. Cardioembolism (CE) common etiology of stroke, yet the association between hepatic fibrosis and CE remains understudied. Aim: This study aims to investigate CE-induced as well its impact on patient prognosis. Methods: retrospective included 344 acute ischemic (AIS) patients who underwent thrombolytic therapy. was assessed using Fibrosis-4 (FIB-4) index Aspartate...

10.2174/0115701611343296250218111614 article EN Current Vascular Pharmacology 2025-02-24

Single-cell RNA sequencing (scRNA-seq) has unveiled extensive cellular heterogeneity, yet precise cell type annotation and the identification of novel populations remain significant challenges. scHeteroNet, a graph neural network framework specifically designed to leverage heterophily in scRNA-seq data, is presented. Unlike traditional methods that assume homophily, scHeteroNet captures complex cell-cell interactions by integrating information from both immediate extended neighborhoods,...

10.1002/advs.202412095 article EN cc-by Advanced Science 2025-03-05

Abstract Background The addition of PD1 blockade to neoadjuvant chemoradiotherapy (CRT) has been shown significantly increase pCR rates in locally advanced rectal cancer (LARC). Yet, its impact on total mesorectal excision (TME) remains unknown. Methods A post-hoc analysis the randomized POLARSTAR trial, which enrolled patients with LARC at eight major colorectal centres Beijing compare CRT plus alone, was undertaken. Patients received one three combinations treatments before TME surgery:...

10.1093/bjs/znaf057 article EN British journal of surgery 2025-03-01

ABSTRACT Discrepancies in serum electrolyte levels have been observed between stroke patients and healthy individuals. Previous studies indicated an association electrolytes all‐cause mortality as well cardiovascular events patients. However, there still lacks comprehensive analysis on the connection negative outcomes hypertensive individuals with early neurological deterioration (END). Totally 1341 treated thrombolysis for acute ischemic at First Affiliated Hospital of Wenzhou Medical...

10.1111/jch.70037 article EN cc-by-nc Journal of Clinical Hypertension 2025-03-31

Abstract Background Long course radiotherapy plus neoadjuvant chemotherapy followed by resection (total mesorectal excision, TME) has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC). Tislelizumab, an anti-PD1 humanized IgG4 monoclonal antibody, been demonstrated with clinical activity and is approved for treating recurrent/refractory classical Hodgkin lymphoma advanced/metastatic urothelial carcinoma China. However, safety efficacy long (neoadjuvant...

10.1186/s12885-022-09554-9 article EN cc-by BMC Cancer 2022-04-27
Coming Soon ...